Table 2.
Characteristics of Patients with Primary Non-adherence and with Ongoing Dispensings by Therapeutic Class Subgroups
| Characteristic (n (%)) | Antidiabetic | Antihypertensive | Antihyperlipidemic | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Primary | Ongoing | p value* | Primary | Ongoing | p value* | Primary | Ongoing | p value* | |
| n = 172 (11%) | n = 1,349 (89%) | n = 331 (7%) | n = 4,390 (93%) | n = 582 (13%) | n = 4,025 (87%) | ||||
| Demographic and enrollment characteristics | |||||||||
| Age group | |||||||||
| ≤49 | 38 (22) | 253 (19) | 0.42 | 96 (29) | 1,316 (30) | 0.81 | 116 (20) | 680 (17) | 0.01 |
| 50–64 | 70 (41) | 532 (39) | 131 (40) | 1,768 (40) | 264 (45) | 1,693 (42) | |||
| 65+ | 64 (37) | 564 (42) | 104 (31) | 1,306 (30) | 202 (35) | 1,652 (41) | |||
| Gender | |||||||||
| Female | 86 (50) | 637 (47) | 0.49 | 161 (49) | 2,288 (52) | 0.22 | 283 (49) | 2,007 (50) | 0.58 |
| Male | 86 (50) | 712 (53) | 170 (51) | 2,102 (48) | 299 (51) | 2,018 (50) | |||
| Race | |||||||||
| Non-Hispanic White | 77 (45) | 720 (53) | 0.14 | 150 (45) | 2,530 (58) | <0.001 | 317 (54) | 2,430 (60) | <0.01 |
| Hispanic | 35 (20) | 211 (15) | 44 (13) | 424 (10) | 73 (13) | 335 (8) | |||
| Other | 21 (12) | 128 (10) | 39 (12) | 369 (8) | 42 (7) | 286 (7) | |||
| Missing/unknown | 39 (23) | 290 (22) | 98 (30) | 1,067 (24) | 150 (26) | 974 (24) | |||
| SES | |||||||||
| Low | 37 (22) | 213 (16) | 0.15 | 55 (17) | 534 (12) | 0.04 | 86 (15) | 461 (11) | 0.06 |
| Not low | 131 (76) | 1,094 (81) | 269 (81) | 3,712 (85) | 475 (82) | 3,432 (85) | |||
| Unknown/missing | 4 (2) | 42 (3) | 7 (2) | 198 (5) | 21 (4) | 132 (3) | |||
| Smoking status | |||||||||
| No tobacco | 138 (80) | 1,174 (87) | 0.02 | 273 (82) | 3,688 (84) | 0.47 | 484 (83) | 3,489 (87) | 0.02 |
| Tobacco | 34 (20) | 175 (13) | 58 (18) | 702 (16) | 98 (17) | 536 (13) | |||
| Enrollment | |||||||||
| <10 years | 73 (42) | 503 (37) | 0.19 | 171 (52) | 1,984 (45) | 0.02 | 278 (48) | 1,704 (42) | 0.01 |
| 10+ years | 99 (58) | 846 (63) | 160 (48) | 2,406 (55) | 304 (52) | 2,321 (58) | |||
| Clinical characteristics | |||||||||
| Quan category | |||||||||
| 0 | 48 (28) | 331 (25) | 0.88 | 174 (53) | 2,496 (57) | 0.34 | 163 (28) | 1,108 (28) | 0.07 |
| 1 | 45 (26) | 356 (26) | 81 (24) | 1,032 (24) | 134 (23) | 1,106 (27) | |||
| 2 | 34 (20) | 279 (21) | 37 (11) | 455 (10) | 105 (18) | 767 (19) | |||
| 3 | 22 (13) | 174 (13) | 17 (5) | 210 (5) | 78 (13) | 459 (11) | |||
| 4+ | 23 (13) | 209 (16) | 22 (7) | 197 (4) | 102 (18) | 585 (15) | |||
| Obese (based on BMI) | |||||||||
| No | 56 (33) | 527 (39) | 0.16 | 188 (57) | 2,365 (54) | 0.02 | 334 (57) | 2,400 (60) | 0.42 |
| Yes | 113(66) | 810 (60) | 132 (40) | 1,958 (45) | 243 (42) | 1,603 (40) | |||
| Unknown/missing | 3 (2) | 12 (1) | 11 (3) | 67 (2) | 5 (1) | 22 (1) | |||
| Utilization, benefits, and insurance | |||||||||
| Office visits/phone/emails 6 months post-index order | |||||||||
| <5 | 70 (41) | 389 (29) | 0.001 | 153 (46) | 1,775 (40) | 0.04 | 258 (44) | 1,751 (44) | 0.71 |
| 5+ | 102 (59) | 960 (71) | 178 (54) | 2,615 (60) | 324 (56) | 2,274 (56) | |||
| Insurance product | |||||||||
| HMO | 162 (94) | 1,258 (93) | 0.69 | 289 (87) | 4,006 (91) | <0.001 | 525 (90) | 3,730 (93) | 0.10 |
| Deduct/coinsurance | 8 (5) | 62 (5) | 19 (6) | 259 (6) | 35 (6) | 173 (4) | |||
| Other | 2 (1) | 29 (2) | 23 (7) | 125 (3) | 22 (4) | 122 (3) | |||
| Office visit copayment | |||||||||
| $0–10 | 37 (22) | 369 (27) | 0.44 | 77 (23) | 1,007 (23) | 0.90 | 137 (24) | 1,129 (28) | 0.05 |
| $11–20 | 27 (16) | 191 (14) | 46 (14) | 679 (15) | 75 (13) | 571 (14) | |||
| >$20 | 44 (26) | 323 (24) | 91 (27) | 1,171 (27) | 150 (26) | 995 (25) | |||
| Coinsurance | 64 (37) | 466 (35) | 117 (35) | 1,533 (35) | 220 (38) | 1,330 (33) | |||
| Prescriber characteristics | |||||||||
| Ordering prescriber department | |||||||||
| Primary care | 158 (92) | 1,238 (92) | 0.97 | 300 (91) | 4,103 (93) | 0.05 | 553 (95) | 3,593 (89) | <0.001 |
| Non-primary care | 14 (8) | 111 (8) | 31 (9) | 287 (7) | 29 (5) | 43 (11) | |||
Characteristics that were not significant within any Therapeutic Class Subgroup are not shown
*Chi-square or Kruskal–Wallis test